(firstQuint)STAAR-2 Clinical Study.

 To assess the effect of Aranesp_ on the hemoglobin (Hgb) of CRI subjects who are recombinant human erythropoietin (rHuEPO)-naive or converting from rHuEPO therapy.

 To assess the association between subject self-reported health-related quality of life (HRQoL) as it relates to Hgb concentration and glomerular filtration rate (GFR) in subjects who were rHuEPO-naive prior to study enrollment.

 To characterize the health-related resource utilization of subjects with CRI.

 To characterize the subject satisfaction with Aranesp_ compared to previous rHuEPO therapy.

 To characterize iron treatment in subjects with CRI.

 To assess the safety profile of Aranesp_ therapy in subjects with CRI.

 STAAR-2 Clinical Study@highlight

To assess the effect of Aranesp on the hemoglobin (Hgb) of CRI subjects who are recombinant human erythropoietin (rHuEPO)-naive or converting from rHuEPO therapy.

